Inspire Investing LLC Grows Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Inspire Investing LLC increased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 30.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 75,313 shares of the biopharmaceutical company’s stock after acquiring an additional 17,541 shares during the quarter. Inspire Investing LLC’s holdings in Sage Therapeutics were worth $409,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in SAGE. State Street Corp boosted its stake in shares of Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after acquiring an additional 451,377 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Sage Therapeutics by 831.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 489,089 shares of the biopharmaceutical company’s stock worth $5,312,000 after purchasing an additional 436,566 shares during the period. Squarepoint Ops LLC lifted its position in Sage Therapeutics by 1,112.0% during the second quarter. Squarepoint Ops LLC now owns 313,407 shares of the biopharmaceutical company’s stock valued at $3,404,000 after purchasing an additional 287,549 shares in the last quarter. RTW Investments LP grew its holdings in Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after purchasing an additional 111,123 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Sage Therapeutics in the second quarter worth about $1,178,000. 99.22% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on SAGE shares. StockNews.com cut Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Robert W. Baird dropped their price target on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. Scotiabank decreased their price objective on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, October 30th. Raymond James restated a “market perform” rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. Finally, TD Cowen cut their price target on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Thursday, November 21st. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.53.

Sage Therapeutics Stock Up 1.1 %

Sage Therapeutics stock opened at $7.10 on Friday. The company’s 50-day moving average price is $5.83 and its 200-day moving average price is $7.34. The company has a market cap of $434.33 million, a PE ratio of -1.27 and a beta of 0.91. Sage Therapeutics, Inc. has a twelve month low of $4.62 and a twelve month high of $27.67.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The company’s revenue was up 337.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.81) earnings per share. As a group, sell-side analysts expect that Sage Therapeutics, Inc. will post -6.47 earnings per share for the current fiscal year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.